FICHA FARMACOLÓGICA de Doxorubicin hydrochloride (pegylated liposomal). Contiene la Monografía en distintos idiomas (de la Comunidad Económica Europea), así como la discusión científica que sustenta su aprobación terapéutica. Para acceder a la monografía en idioma español, hacer doble clik en la sigla (es) en la fila que se sitúa más abajo del centro de la página oficial. Cerasale. Marzo 09, 2009.
abrir aquí:
EPARs for authorised medicinal products for human use - Caelyx
Active Substance
Doxorubicin hydrochloride (pegylated liposomal)
International Nonproprietary Name or Common Name
Doxorubicin hydrochloride
Pharmaco-therapeutic Group
Cytotoxic agents (anthracyclines and related substances)
ATC Code
L01DB
Therapeutic Indication:
Caelyx is indicated:
- As monotherapy for patients with metastatic breast cancer, where there is an increased cardiac risk
- For treatment of advanced ovarian cancer in women who have failed a first-line platinum-based chemotherapy regimen
- In combination with bortezomib for the treatment of progressive multiple myeloma in patients who have received at least one prior therapy and who have already undergone or are unsuitable for bone marrow transplant
- For treatment of AIDS-related Kaposi’s sarcoma (KS) in patients with low CD4 counts (< 200 CD4 lymphocytes/mm3) and extensive mucocutaneous or visceral disease.
Caelyx may be used as first-line systemic chemotherapy, or as second line chemotherapy in AIDS-KS patients with disease that has progressed with, or in patients intolerant to, prior combination systemic chemotherapy comprising at least two of the following agents: a vinca alkaloid, bleomycin and standarddoxorubicin (or other anthracycline)
No hay comentarios:
Publicar un comentario